Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7156 to 7170 of 7702 results

  1. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)

    This guidance has been updated and replaced by NICE technology appraisal guidance 386.

    Technology appraisal guidance
    Published
    26 June 2013

  2. Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)

    The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.

    Technology appraisal guidance
    Published
    26 June 2013

  3. Lubiprostone for treating chronic idiopathic constipation (TA318)

    This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza).

    Technology appraisal guidance
    Published
    23 July 2014

  4. Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (TA295)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA421.

    Technology appraisal guidance
    Published
    28 August 2013

  5. Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (TA296)

    This guideance has been updated and replaced by NICE technology appraisal guidance 422.

    Technology appraisal guidance
    Published
    25 September 2013

  6. Ocriplasmin for treating vitreomacular traction (TA297)

    We have withdrawn this guidance. Inceptua has stopped marketing Ocriplasmin (Jetrea) and its marketing authorisation has been withdrawn.

    Technology appraisal guidance
    Published
    23 October 2013

  7. Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309)

    This guidance has been updated and replaced by NICE technology appraisal guidance 402.

    Technology appraisal guidance
    Published
    23 April 2014

  8. The clinical effectiveness and cost effectiveness of sibutramine for obesity (TA31)

    This guidance has been replaced by NICE guideline CG43. 

    Technology appraisal guidance
    Published
    28 October 2001

  9. Golimumab for the treatment of methotrexate-naive rheumatoid arthritis (terminated appraisal) (TA224)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    22 June 2011

  10. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Technology appraisal guidance
    Published
    23 January 2013

  11. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (TA248)

    This guidance has been updated and replaced by NICE guideline NG28.

    Technology appraisal guidance
    Published
    22 February 2012

  12. Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)

    This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.

    Technology appraisal guidance
    Published
    3 April 2012

  13. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (TA251)

    This guidance has been updated and replaced by NICE technology appraisal guidance 426.

    Technology appraisal guidance
    Published
    25 April 2012

  14. Guidance on the use of gemcitabine for the treatment of pancreatic cancer (TA25)

    This guidance has been replaced by NICE guideline NG85.

    Technology appraisal guidance
    Published
    8 May 2001

  15. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

    Technology appraisal guidance
    Published
    25 April 2012